Combination Chemotherapy with Irinotecan and Ifosfamide as Second-Line Treatment of Refractory or Sensitive Relapsed Small Cell Lung Cancer: A Phase II Study
| Autor: | Masao Ichiki, Rumi Gohara, Toru Rikimaru, Takao Kitajima, Akiko Shimada, Hisamichi Aizawa, Rei Fujiki |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Phases of clinical research Irinotecan Small-cell carcinoma chemistry.chemical_compound Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols Drug Discovery medicine Humans heterocyclic compounds Pharmacology (medical) Ifosfamide Carcinoma Small Cell Antineoplastic Agents Alkylating neoplasms Aged Pharmacology Chemotherapy business.industry Combination chemotherapy General Medicine Middle Aged medicine.disease Antineoplastic Agents Phytogenic digestive system diseases Nitrogen mustard respiratory tract diseases Surgery Survival Rate Treatment Outcome Infectious Diseases chemistry Camptothecin Female business medicine.drug |
| Zdroj: | Chemotherapy. 49:200-205 |
| ISSN: | 1421-9794 0009-3157 |
| DOI: | 10.1159/000071145 |
| Popis: | This phase II study was conducted to investigate the efficacy and safety of irinotecan (CPT-11) and ifosfamide as second-line chemotherapy for relapsed small cell lung cancer (SCLC). Eligibility criteria included histologically or cytologically confirmed SCLC, prior chemotherapy including platinum + etoposide, and measurable or evaluable disease. CPT-11 (80 mg/m2) was administered intravenously on days 1, 8 and 15, while ifosfamide (1.5 g/m2) was given on days 1 through 3 every 4 weeks. Thirty-four patients (29 men) with a median age of 69 years (range 42–77) and a median Eastern Cooperative Oncology Group (ECOG) performance status of 1 (range 0–2) were enrolled. The response rate was 52.9% (95% confidence interval: 29.8–64.9%) with 2 complete responses and 16 partial responses. Our analyses of prognostic factors showed risk factors assessed before receiving second-line chemotherapy, which were the number of metastatic sites, performance status and the type of relapse. WHO grade 3–4 neutropenia was recorded in 52.9% of the patients, grade 3 diarrhea in 5.9%. The combination of CPT-11 and ifosfamide demonstrated clinical efficacy in relapsed SCLC with a favorable toxicity profile, particularly for performance status 0–1 and sensitive cases with only one metastatic site. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|